Published in Eur J Immunol on March 01, 2007
T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat Immunol (2008) 4.52
Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time. Immunity (2010) 2.82
T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology (2009) 1.85
Fast on-rates allow short dwell time ligands to activate T cells. Proc Natl Acad Sci U S A (2010) 1.43
Thermodynamics of T-cell receptor-peptide/MHC interactions: progress and opportunities. J Mol Recognit (2008) 1.34
Structural and biophysical determinants of αβ T-cell antigen recognition. Immunology (2012) 1.30
Antigen availability determines CD8⁺ T cell-dendritic cell interaction kinetics and memory fate decisions. Immunity (2013) 1.09
A comprehensive calorimetric investigation of an entropically driven T cell receptor-peptide/major histocompatibility complex interaction. Biophys J (2007) 1.04
Limited expansion of virus-specific CD8 T cells in the aged environment. Mech Ageing Dev (2009) 1.04
T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells. Clin Exp Immunol (2015) 0.88
Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4⁺ T-cell repertoire selection. Nat Commun (2012) 0.86
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. Front Immunol (2015) 0.80
Viral Escape Mutant Epitope Maintains TCR Affinity for Antigen yet Curtails CD8 T Cell Responses. PLoS One (2016) 0.75
Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets. J Immunol (2016) 0.75
Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature (1995) 7.40
Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature (1990) 5.41
Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol (1998) 5.11
HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci U S A (1992) 5.02
Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol (2001) 3.56
Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell (1990) 3.44
Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol (2005) 2.97
Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat Immunol (2001) 2.83
Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng (2003) 2.75
Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T cell activation. Mol Cell (2003) 2.61
Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response. J Exp Med (2005) 2.57
Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med (1997) 2.47
Negative selection--clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol (2003) 2.42
TCR binding to peptide-MHC stabilizes a flexible recognition interface. Immunity (1999) 2.33
Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med (2005) 2.22
TCR affinity and negative regulation limit autoimmunity. Nat Med (2004) 1.94
BirA enzyme: production and application in the study of membrane receptor-ligand interactions by site-specific biotinylation. Anal Biochem (1999) 1.81
T cell homeostasis: keeping useful T cells alive and live T cells useful. Semin Immunol (2005) 1.80
Altered peptide ligands induce delayed CD8-T cell receptor interaction--a role for CD8 in distinguishing antigen quality. Immunity (2006) 1.63
Mature T cell reactivity altered by peptide agonist that induces positive selection. J Exp Med (1996) 1.50
Structural and thermodynamic correlates of T cell signaling. Annu Rev Biophys Biomol Struct (2001) 1.49
Thermodynamics of T cell receptor binding to peptide-MHC: evidence for a general mechanism of molecular scanning. Proc Natl Acad Sci U S A (1999) 1.47
The TCR triggering puzzle. Immunity (2001) 1.36
Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol (2000) 1.13
Disparate thermodynamics governing T cell receptor-MHC-I interactions implicate extrinsic factors in guiding MHC restriction. Proc Natl Acad Sci U S A (2006) 1.12
Peptide-induced T cell receptor down-regulation on naive T cells predicts agonist/partial agonist properties and strictly correlates with T cell activation. Eur J Immunol (1997) 1.11
TCR binding kinetics measured with MHC class I tetramers reveal a positive selecting peptide with relatively high affinity for TCR. J Immunol (2003) 1.05
Emergence of virus escape mutants after immunization with epitope vaccine. J Virol (1995) 1.01
Viral escape at the molecular level explained by quantitative T-cell receptor/peptide/MHC interactions and the crystal structure of a peptide/MHC complex. J Mol Biol (2000) 0.94
Weak agonist self-peptides promote selection and tuning of virus-specific T cells. Eur J Immunol (2003) 0.78
mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 10.07
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68
Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med (2005) 3.63
Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol (2005) 3.14
CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest (2008) 3.11
Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol (2008) 2.97
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet (2008) 2.77
Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science (2007) 2.67
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med (2008) 2.64
Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol (2004) 2.59
Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med (2002) 2.54
Brain anatomy and sensorimotor gating in Asperger's syndrome. Brain (2002) 2.26
The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol (2004) 2.11
A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One (2008) 2.07
A single autoimmune T cell receptor recognizes more than a million different peptides. J Biol Chem (2011) 2.06
Human TCR-binding affinity is governed by MHC class restriction. J Immunol (2007) 2.02
GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med (2008) 1.99
Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J Biol Chem (2007) 1.95
TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol (2007) 1.95
Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J Immunol (2005) 1.94
The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. J Biol Chem (2003) 1.92
Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem (2005) 1.92
The coming of age of virus-like particle vaccines. Biol Chem (2008) 1.85
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol (2006) 1.84
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol (2005) 1.84
Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology (2009) 1.78
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol (2006) 1.75
T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res (2012) 1.74
Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol (2004) 1.74
Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity (2011) 1.70
CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One (2006) 1.68
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens (2007) 1.68
CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity (2005) 1.63
Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods (2008) 1.62
Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol (2006) 1.59
Monoclonal TCR-redirected tumor cell killing. Nat Med (2012) 1.57
CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc Natl Acad Sci U S A (2009) 1.56
T cell receptor cross-reactivity directed by antigen-dependent tuning of peptide-MHC molecular flexibility. Immunity (2009) 1.55
Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res (2010) 1.52
Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem (2009) 1.51
VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest (2006) 1.51
Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides. Eur J Immunol (2014) 1.49
Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol (2010) 1.48
A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine (2002) 1.48
Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat Immunol (2012) 1.46
T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res (2005) 1.43
Slit2 involvement in glioma cell migration is mediated by Robo1 receptor. J Neurooncol (2007) 1.41
Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology (2008) 1.40
Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol (2002) 1.39
A neuropsychological investigation of male premutation carriers of fragile X syndrome. Neuropsychologia (2004) 1.38
Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol (2011) 1.37
Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov (2010) 1.36
Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett (2004) 1.36
Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial. J Bone Miner Res (2013) 1.36
Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity (2008) 1.34
Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proc Natl Acad Sci U S A (2011) 1.33
Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol (2010) 1.32
Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol (2008) 1.30
Structural and biophysical determinants of αβ T-cell antigen recognition. Immunology (2012) 1.30
Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition. J Biol Chem (2004) 1.29
Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation (2003) 1.29
In vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in autism. Am J Psychiatry (2006) 1.29
Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers. Cytometry A (2008) 1.26
Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol (2003) 1.26
The COMT val158met polymorphism and brain morphometry in healthy young adults. Neurosci Lett (2006) 1.25
Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. Eur J Immunol (2007) 1.24
Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res (2010) 1.21
Interleukin-6 is crucial for recall of influenza-specific memory CD4 T cells. PLoS Pathog (2008) 1.21
Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses. Proc Natl Acad Sci U S A (2005) 1.21
CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. J Immunol (2005) 1.21
Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection. PLoS Pathog (2010) 1.18
T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. Mol Immunol (2008) 1.18
Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res (2008) 1.15
CD8 controls T cell cross-reactivity. J Immunol (2010) 1.15
A structural voyage toward an understanding of the MHC-I-restricted immune response: lessons learned and much to be learned. Immunol Rev (2012) 1.14
Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A (2008) 1.14
Peptide length determines the outcome of TCR/peptide-MHCI engagement. Blood (2012) 1.13
A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol (2007) 1.13
Rapid response of marginal zone B cells to viral particles. J Immunol (2004) 1.13
Regulating the immune response to tumours. Adv Drug Deliv Rev (2006) 1.13
Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span. J Immunol (2007) 1.12
Versatile virus-like particle carrier for epitope based vaccines. PLoS One (2010) 1.12
Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol (2010) 1.11
Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs (2007) 1.11
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol (2006) 1.11
Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol (2002) 1.10
Innate immunity together with duration of antigen persistence regulate effector T cell induction. J Immunol (2003) 1.09
Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol (2012) 1.09